Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acquired thrombotic thrombocytopenic purpura is the non-hereditary form of thrombotic thrombocytopenic purpura (TTP), characterized by profound peripheral thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and single or multiple organ failure of variable severity.
Biomarker and diagnostic research for acquired thrombotic thrombocytopenic purpura has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
4 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and medical devices. Pipeline includes 2 PHASE2. Research is primarily sponsored by academic and government institutions.
139 publications have been identified in PubMed for acquired thrombotic thrombocytopenic purpura. Research spans Review / Meta-Analysis (34%), Case Report / Case Series (22%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 47 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:52 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies | 31 | 22% |
Disease patterns and progression | 25 | 18% |
Testing and diagnosis research | 12 | 9% |
Laboratory research | 8 | 6% |
Other research | 7 | 5% |
Clinical study results | 6 | 4% |
New treatment approaches | 3 | 2% |
Nóbrega TDR (2026). [PMID: 41548312](https://pubmed.ncbi.nlm.nih.gov/41548312/). *Thromb Res*. [Epidemiology / Natural History]
Elkourashy SA (2026). [PMID: 41852235](https://pubmed.ncbi.nlm.nih.gov/41852235/). *J Int Med Res*. [Case Report / Case Series]
Li Z (2026). [PMID: 41390106](https://pubmed.ncbi.nlm.nih.gov/41390106/). *J Thromb Haemost*. [Epidemiology / Natural History]
Kühne L (2026). [PMID: 41159657](https://pubmed.ncbi.nlm.nih.gov/41159657/). *Am J Hematol*. [Other]
Muralt T (2026). [PMID: 42266695](https://pubmed.ncbi.nlm.nih.gov/42266695/). *Front Immunol*. [Review / Meta-Analysis]
Belakova KM (2026). [PMID: 41766954](https://pubmed.ncbi.nlm.nih.gov/41766954/). *Ther Adv Hematol*. [Case Report / Case Series]
Halkidis K (2026). [PMID: 41917369](https://pubmed.ncbi.nlm.nih.gov/41917369/). *Methods Mol Biol*. [Gene Therapy / Novel Therapeutics]
Cornette M (2026). [PMID: 40999880](https://pubmed.ncbi.nlm.nih.gov/40999880/). *Int J Lab Hematol*. [Diagnostic / Biomarker]
Agosti P (2026). [PMID: 41481565](https://pubmed.ncbi.nlm.nih.gov/41481565/). *Blood Transfus*. [Epidemiology / Natural History]
Schimmer R (2026). [PMID: 42078821](https://pubmed.ncbi.nlm.nih.gov/42078821/). *Res Pract Thromb Haemost*. [Clinical Trial Publication]
AI-curated news mentioning acquired thrombotic thrombocytopenic purpura
Updated Sep 11, 2026
A case report highlights pancreatitis and myocardial infarction as complications of thrombotic thrombocytopenic purpura (TTP). This finding underscores the need for awareness of these potential severe outcomes in TTP patients.
A recent study highlights the psychological health, cognition, and overall well-being impacts of hereditary thrombotic thrombocytopenic purpura (TTP) on patients. The findings underscore the need for comprehensive care approaches that address both physical and mental health aspects.